Targeting a specific cancer marker in pancreatic cancer
Official title: Targeting Disease Specific Tn Antigen in Pancreatic Cancer
Funded at University of Louisville · NIH-11327964 · Data updated 2026-11-12
This study is looking at a tough type of pancreatic cancer to find new treatments that can better target certain markers on cancer cells, with the hope of improving outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | December 20, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $433,763 |
| NIH project number | 7R01CA288372-02 |
| Project ID | NIH-11327964 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with advanced or metastatic disease.
✕Less likely to help
Patients with early-stage pancreatic cancer or those whose tumors do not express Tn or Sialyl Tn antigens may not benefit from this research.
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. It aims to develop new therapies that target specific carbohydrate antigens (Tn and Sialyl Tn) found on the surface of cancer cells, which are linked to poor patient outcomes. The study will investigate how these antigens influence cancer growth and spread, and how a novel monoclonal antibody can effectively target and destroy these cancer cells. By understanding the role of these antigens, the research seeks to improve treatment responses for patients with advanced PDAC.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting similar cancer-associated antigens, indicating potential for success with this novel approach.
Where this research is happening
-
University of Louisville
Louisville, United States Active
Researchers
- Principal investigator: Radhakrishnan, Prakash — University of Louisville
- Study coordinator: Radhakrishnan, Prakash
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.